Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Uzatresgene autoleucel - US WorldMeds

Next Previous
Drug Profile

Uzatresgene autoleucel - US WorldMeds

Alternative Names: ADP-5701; ADP‑A2M4CD8; Autologous genetically modified ADP-A2M4CD8 cells; Melanoma-associated antigen A4-specific T-cells co-expressing CD8 alpha - Adaptimmune; uza-cel

Latest Information Update: 11 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Adaptimmune
  • Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Gastric cancer; Oesophageal cancer; Ovarian cancer
  • Phase I Solid tumours

Most Recent Events

  • 11 Nov 2025 Adaptimmune terminates enrollment in the phase-II SURPASS-3 clinical trials in Ovarian cancer (Monotherapy, Combination therapy, In adults, In the elderly, Late-stage disease, Second-line therapy or greater) in the USA, United Kingdom, Spain, France, Canada (IV) (NCT05601752) (Adaptimmune pipeline, November 2025)
  • 11 Nov 2025 Adaptimmune terminates enrollment in the phase-I clinical trials in Solid tumours (In adults, In the elderly) in France, United Kingdom, USA, Belgium, Canada, Spain (IV) prior to November 2025 (NCT04044859) (Adaptimmune pipeline, November 2025)
  • 21 Oct 2025 Galapagos NV plans to wind down cell therapy therapeutics as per business strategy

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top